Researchers develop way to measure abundance of 12 different complement proteins in the urine.

Which of the following is true regarding the epidemiology of hypertriglyceridemia?

A. Triglyceride levels increase gradually in women until about age 50 years and then decline slightly.
B. Triglyceride levels in men continue to increase with age.
C. Mild hypertriglyceridemia (triglyceride level greater than 150 mg/dL) is slightly more prevalent in women beginning at age 30 years and in men at the age of 60 years.
D. Non-Hispanic black persons often have lower triglyceride levels than white persons.

Follow the link for the answer.

From your experience, which is the best way to educate your patients who have type 2 diabetes and do not take insulin?

- Individual personal classes
- Group classes
- Online classes
- Recommend a book
- Brochures and pamphlets

Follow the link to share your experience.

In this week's Homerun Slides, round 3 in the pituitary category from Dr. Claude Lardinois' Endocrinology Jeopardy. This week's clue is visual, so click to see what it is!

The hexosamine/O-linked N-acetyl glucosamine pathway: One metabolic fate of glucose is the hexosamine biosynthetic pathway (HBP), and high flux through this pathway, such as occurs in diabetes or overnutrition, has been convincingly linked to insulin resistance and beta-cell failure. In this pathway a relatively small fraction of cellular glucose flux—a few percent in most tissues—is converted to UDP-N-acetylglucosamine (UDP-GlcNAc) and other amino sugars. The rate limiting step is catalyzed by the enzyme glutamine: fructose-6-phosphate amidotransferase (GFA) that catalyzes the synthesis of glucosamine-6-P from fructose-6-P and glutamine.

Researchers suggest implementation of cardioprotective medications sooner than current guideline recommendations.

Adding an SGLT2 inhibitor helps lower HbA1c and decrease variability in glucose ranges among people with type 1 diabetes.

Researchers study efficacy and safety of GLP-1 inhibitors on weight loss.

New study focuses on cardiovascular safety of weight loss drug in patients with excess weight or obesity.

The SUMMIT VIP study shows conventional risk factors do not suffice in predicting heart complications.